The effect of group cognitive behavior combined hypnotherapy on neuroendocrine and physical symptoms in patients with anxiety disorders

Not Applicable

• Conditions: Anxiety disorders; Mental and Behavioural Disorders

• Registration Number: ISRCTN45667531
• Lead Sponsor: niversiti Sains Malaysia

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-07-01
• Last Update Posted: 10 July 2023
• Study Completion: 2024-12-31

Recruitment & Eligibility

• Status: Ongoing
• Sex: All
• Target Recruitment: 84

Inclusion Criteria

1. ICD-10 diagnosis of generalized anxiety disorder, social anxiety disorder and panic disorder
2. Anxiety disorder lasting more than 3 months but not more than 3 years
3. Ability to express and understand simple Chinese characters
4. Informed consent and voluntary participation in the study

Exclusion Criteria

1. Patients with major psychiatric disorders such as depression and bipolar disorder
2. Patients at serious risk of suicide and self-injury
3. Patients with serious cardiovascular diseases such as severe hypertension, diabetes, hyperlipidemia
4. Patients who have had substance dependence or abuse, such as alcohol or drug dependence
5. Pregnant women

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Measured at baseline week 0 and after treatment at week 6:<br>1. Anxiety levels in patients with anxiety disorders measured using the Hamilton Anxiety Inventory (HAMA) and Self-Assessment Scales for Anxiety (SAS)<br>2. Somatic symptoms in patients with anxiety disorders measured using the Somatization Symptom Checklist (SSS)

Secondary Outcome Measures

Name	Time	Method
euroendocrine levels (plasma cortisol [COR], serum triiodothyronine [T3], thyroid hormone [T4] and thyroid stimulating hormone [TSH]) measured using blood samples at baseline week 0 and after the intervention at week 6